Takeda Gmbh

Nycomed Gmbh

Katairo Gmbh

Takeda Pharmaceutical Company Limited

Guido Hanauer

Beate Schmidt

Wilhelm Wurst

Daniela Hauser

Jörg Senn-Bilfinger

Bernhard Kohl

Hans-Peter Kley

Michael W Burnet

Rolf-Peter Hummel

Masatoshi Hazama

Ernst Sturm

Bernd Müller

Wolfgang-Alexander Simon

Ulrich Schraermeyer

Dirk Bredenbroeker

Joerg Kemkowski

Yuichiro Amano

Wolfgang Kromer

Stefan Postius

Reinhard Huber

Hiroshi Nagabukuro

Sham Nikam

Dirk Bredenbröker

Jörg Kemkowski

Bernd MÜLLER

Jorg Senn-Bilfinger

Michael Burnet

The present invention is directed to the treatment of idiopathic pulmonary fibrosis with (a) a phosphodiesterase 4 inhibitor or (b) a phosphodiesterase 4 inhibitor and a second active pharmaceutical ingredient.

Treatment of idiopathic pulmonary fibrosis

The present invention is directed to methods for the treatment of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steato-hepatitis (NASH) with a phosphodiesterase 4 (PDE4) inhibitor.

Treatment of nonalcoholic fatty liver disease

A method for selecting a compound or a composition suitable for treating lipofuscin associated diseases in a patient, the method including the steps of determining a reactivity factor, determining a targeting factor that allows an uptake into a cell and a provides a targeting of lipofuscin, and selecting a compound or a composition or combining compounds to obtain a compound or composition that comprises a reactivity factor and an targeting factor.

Methods for the determination of compounds or compositions for the treatment of lipofuscin related diseases and compounds or compositions

The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2.

Roflumilast for the treatment of diabetes mellitus type 2

The invention relates to the use of Roflumilast and/or Roflumilast N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention additionally relates to combinations of Roflumilast and/or Roflumilast N-Oxide with other active agents for the treatment of diabetes mellitus.

Roflumilast for the treatment of diabetes mellitus

The invention relates to (&#x2212;)-pantoprazole magnesium and its hydrates and to medicaments comprising these compounds.

Salt of (S)-pantoprazole and its hydrates

Growing community of inventors

Constance, Germany

Guido Hanauer